Abstracts tagged "disease-modifying antirheumatic drugs and rheumatoid arthritis (RA)"

Abstract Number: 1138 • 2019 ACR/ARP Annual Meeting
Outpatient Costs and Evaluation and Management (E&M) Expenditure Trends in Rheumatoid Arthritis (RA) Patients Treated with Biologic Therapies in US Community Practices
Colin Edgerton¹, Janna Radtchenko ² and V. Michael Holers ³, ¹Articularis Healthcare, Charleston, ²Trio Health, La Jolla, CA, ³University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver
Background/Purpose: RA is an autoimmune disease affecting over 1.5 million Americans. Biologic disease-modifying antirheumatic drugs (bDMARDs) expanded treatment choices for RA patients (pts) in the…
Abstract Number: 2360 • 2019 ACR/ARP Annual Meeting
Safety of Biological DMARD in Patients with Interstitial Lung Disease from a Chilean Cohort of Patients with Rheumatoid Arthritis
Silvana Saavedra¹, Karen Vergara ², Claudia Hernandez ², Pedro Zamorano ², Annelise Goecke ², Luis Toro ² and FELIPE REYES ¹, ¹HOSPITAL CLINICO UNIVERSIDAD DE CHILE, Santiago, Chile, ²HOSPITAL CLINICO UNIVERSIDAD DE CHILE, Santiago, Region Metropolitana, Chile
Background/Purpose: Interstitial lung disease (ILD) is a common pulmonary manifestation of rheumatoid arthritis (RA) that may be related to the inflammatory process itself, to infectious…
Abstract Number: 2394 • 2017 ACR/ARHP Annual Meeting
Differential Effect of Corticosteroids and Biological Dmards on Five-Year Radiographic Progression in Rheumatoid Arthritis: Results from a Weighted Cumulative Exposure Model Developed on the Espoir Cohort
Baptiste Louveau¹, Yann De Rycke¹, Alexandre Lafourcade¹, Alain Saraux², Francis Guillemin³, Florence Tubach⁴, Bruno Fautrel⁵ and David Hajage¹, ¹APHP, Pitié Salpêtrière Hospital, Département Biostatistics and Public health, Pharmacoepidémiology center (Cephepi), 75018 75013, Paris, France, Paris, France, ²Rheumatology Department, Rheumatology Department, CHU de la Cavale Blanche, Brest, France, Brest Cedex, France, ³University of Lorraine, Nancy, France, Nancy, France, ⁴Université Pierre et Marie Curie (UPMC)-Paris 6; APHP, Pitié Salpêtrière Hospital, Département Biostatistics and Public health, Pharmacoepidémiology center (Cephepi), 75018 75013, Paris, France, Paris, France, ⁵UPMC University Paris 06, Pitié-Salpétrière Hospital, Paris, France
Background/Purpose: In rheumatoid arthritis (RA), a strategic approach to achieve low-disease activity or remission is now recommended. Controlling joint damage is thus an important concern…
Abstract Number: 2415 • 2014 ACR/ARHP Annual Meeting
Characteristics of Rheumatoid Arthritis Patients Not Receiving Early Initiation of Disease Modifying Therapy
Dimitrios A. Pappas^1,2, Jeffery D. Kent³, Jeffrey D. Greenberg^2,4, Marc Mason², Joel M. Kremer⁵, Amy Y. Grahn³ and Robert J. Holt⁶, ¹Columbia University, New York, NY, ²Corrona, LLC., Southborough, MA, ³Horizon Pharma, Inc., Deerfield, IL, ⁴Rheumatology, New York University School of Medicine, New York, NY, ⁵Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, ⁶University of Illinois - Chicago, Chicago, IL
Background/Purpose : Early and aggressive therapy of Rheumatoid Arthritis (RA) with Disease Modifying Anti-Rheumatic Agents (DMARDs), glucocorticoids, and biologic agents is recommended by current treatment…
Abstract Number: 1424 • 2013 ACR/ARHP Annual Meeting
Persistence On Single Disease Modifying Anti-Rheumatic Drug Therapy In US Veterans With Rheumatoid Arthritis Is Extremely Rare
Jonathan Kruger¹, Ted R. Mikuls² and Grant W. Cannon³, ¹Salt Lake City VA and University of Utah, Salt Lake City, UT, ²Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ³Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT
Background/Purpose: A limited number of rheumatoid arthritis (RA) patients are managed with a single disease-modifying anti-rheumatic drug (DMARD). Previous studies have suggested that DMARD naïve…
Abstract Number: 1412 • 2013 ACR/ARHP Annual Meeting
Use Of a Biologic Marker For An Integrated Pharmacodynamic and Clinical Analysis To Inform Further Clinical Development, Including Dose Selection For The Phase 2b Trial – Treat 2b – Of Tregalizumab In Rheumatoid Arthritis
Eva Dokoupilova¹, Slawomir Jeka², Jiri Vencovsky³, Janusz Badurski⁴, Klaas Prins⁵, Vibeke Strand⁶, Edward C. Keystone⁷, Ronald F van Vollenhoven⁸, Jurgen Wollenhaupt⁹, Andrea Wartenberg-Demand¹⁰, Gabriele Niemann¹⁰, Ahmed Abufarag¹⁰, Silke Aigner¹⁰, Sibylle Kaiser¹⁰, Faiza Rharbaoui¹⁰, Niklas Czeloth¹¹, Ralf Wolter¹⁰, Benjamin Dälken¹⁰ and Thorsten Holzkämper¹⁰, ¹Medical Plus s.r.o, Uherske Hradiste, Czech Republic, ²Clinic of Rheumatology and Connective Tissue Diseases University Hospital No 2 in Bydgoszcz Collegium Medicum UMK in Torun, Bydgoszcz, Poland, ³Institute of Rheumatology, Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴Center of Osteoporosis and Osteo-articular Diseases, Bialystock, Poland, ⁵qPharmetra, Nijmegen, Netherlands, ⁶Adjunct, Division of Immunology / Rheumatology, Stanford University, Portola Valley, CA, ⁷Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁸ClinTRID, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁹Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ¹⁰Biotest AG, Dreieich, Germany, ¹¹Global Research Immunology, Biotest AG, Dreieich, Germany
Background/Purpose: In patients with rheumatoid arthritis (RA) reduced numbers and functional impairment of regulatory T cells (Tregs) have been observed. Tregalizumab is a humanized, agonistic…
Abstract Number: 1338 • 2013 ACR/ARHP Annual Meeting
Time To Institution Of Disease Modifying Anti-Rheumatic Drugs In Australian Patients With Early Rheumatoid Arthritis
Sharon Van Doornum¹, Joanne Tropea², Mark Tacey¹ and Danny Liew¹, ¹Melbourne EpiCentre, The University of Melbourne, Melbourne, Australia, ²Melbourne EpiCentre, Royal Melbourne Hospital, Melbourne, Australia
Background/Purpose: Early introduction of disease-modifying anti-rheumatic drugs (DMARDs) has been shown to reduce joint destruction and long-term disability in rheumatoid arthritis (RA). Substantial and irreversible…
Abstract Number: 390 • 2013 ACR/ARHP Annual Meeting
Autonomic Dysfunction In Rheumatoid Arthritis Improves With Disease Modifying Anti Rheumatic Drugs
Ashit Syngle¹, Inderjeet Verma², Pawan Krishan³ and Nidhi Garg³, ¹Cardio Rheuma, Healing Touch City Clinic, Fortis Multispeciality Hospital, Chandigarh, India, ²Deptt. of Pharmaceutical Sciences & Drug Resaerch, Punjabi University Patiala, India, Chandigarh, India, ³Deptt. of Pharmaceutical Sciences & Drug Research, Punjabi University Patiala, India, Patiala, India
Background/Purpose: Autonomic (AN) function is impaired in rheumatoid arthritis (RA) and is a significant risk predictor of sudden cardiac death. However, even half a century…